• Newbury Pharmaceuticals won two Swedish hospital tenders for Irinotecan Amarox 20 mg/ml, marking its entry into Sweden's hospital tender market.
• The Västra Götalandsregionen contract runs for two years, with a potential extension, and is expected to start in February 2027.
• The Norra sjukvårdsregionen contract runs for four years, with an expected start in March 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Newbury Pharmaceuticals AB published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.